The Clinical Potential of Pretreatment Serum Testosterone Level to Improve the Efficiency of Prostate Cancer Screening{A figure is presented}

European Urology

Volumn 51, Issue 2, 2007, Pages 375-380

  Yano, Masashi ^a   Imamoto, Takashi ^a   Suzuki, Hiroyoshi ^a   Fukasawa, Satoshi ^a   Kojima, Satoko ^a   Komiya, Akira ^a   Naya, Yukio ^a   Ichikawa, Tomohiko ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Gleason score; Prostate biopsy; Prostate cancer; Testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE DISEASE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 33845581658     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.08.047     Document Type: Article

References (22)

1. Chan J.M., Stampfer M.J., and Giovannucci E.L. What causes prostate cancer? A brief summary of the epidemiology. Semin Cancer Biol 8 (1998) 263-273
2. Ekman P. Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts. Eur Urol 35 (1999) 362-369
3. Gann P.H., Hennekens C.H., Ma J., Longcope C., and Stampfer M.J. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88 (1998) 1118-1126
4. Ritva H., Kimmo A., Markku H.V., et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma. Cancer 86 (1999) 312-315
5. Catalona W.J., Southwick P.C., Slawin K.M., et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 56 (2000) 255-260
6. Kikuchi E., Nakashima J., Ishibashi M., et al. Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma. Cancer 89 (2000) 842-849
7. Brawer M.K., Cheli C.D., Neaman I.E., et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 164 (2000) 1671-1672
8. Ito K., Yamamoto T., Kubota Y., et al. Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology 56 (2000) 278-282
9. Huggins C., Stevens R.E., and Hodges C.V. Studies on prostatic cancer: II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 43 (1941) 209-212
10. Shaneyfelt T., Husein R., Bubley G., and Mantzoros C.S. Hormonal predictors of prostate cancer: a meta-analysis [related articles]. J Clin Oncol 18 (2000) 847-853
11. Ishikawa S., Soloway M.S., Van der Zwaag R., and Todd B. Prognostic factors in survival free progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 141 (1989) 1139-1142
12. Ribeiro M., Ruff P., and Falkson G. Low testosterone and a younger age predict a poor outcome in metastatic prostate cancer. Am J Clin Oncol 20 (1997) 605-608
13. Hoffmann M., De Wolf W., and Morgenthaler A. Is low serum free testosterone a marker for high grade prostate cancer?. J Urol 163 (2000) 824-827
14. Massengill J.C., Sun L., Moul J.W., et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169 (2003) 1670-1675
15. Imamoto T., Suzuki H., Fukasawa S., et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 47 (2005) 308-312
16. Schatzl G., Reiter W.J., Thürridl T., et al. Endocrine patterns in patients with benign and malignant prostatic disease. Prostate 44 (2000) 219-224
17. Schatzl G., Madersbacher S., Thürridl T., Waldmüller J., Kramer G., Haitel A., et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47 (2001) 52-58
18. Miller L.R., Partin A.W., Chan D.W., et al. Influence of radical prostatectomy on serum hormone levels. J Urol 160 (1988) 449-453
19. Zhang P.L., Rosen S., Veeramachaneni R., Kao J., DeWolf W.C., and Bubley G. Association between prostate cancer and serum testosterone levels. Prostate 53 (2002) 179-182
20. Lokeshwar B.L., Hurkadli K.S., Sheth A.R., and Block N.L. Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor. Cancer Res 53 (1993) 4855-4859
21. Risbridger G., Thomas T., Gurusinghe C.J., and McFarlane J.R. Inhibin-related proteins in rat prostate. J Endocrinol 149 (1996) 93-99
22. Ying S.Y., Zhang Z., and Huang G. Expression and localization of inhibin/activin subunits and activin receptors in the normal rat prostate. Life Sci 60 (1997) 397-401